Startup · $4.5m raised · Healthcare
Pioneering research into the therapeutic potential of psychedelics for mental health
Melbourne, VIC
Every investor coverage indicates participated in a round Psychae Therapeutics raised.
| Investor | Rounds | Invested |
|---|---|---|
| Genesis Pre-Seed Fund | Pre-seed | - |
| Tin Alley Ventures | Pre-seed | - |
| University of Melbourne's pre-seed investment fund | Pre-seed | - |
Companies Psychae Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Daniel Perkins | Co-founder and co-CEO | Forbes Australia, SmartCompany |
| Dr Jerome Sarris | Founder | Forbes Australia, Startup Daily, SmartCompany |
Stories naming Psychae Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Australian Catholic University signs on as the seventh university in Breakthrough Victoria's co-investment platform, with matched funding pledged; the article also recaps four earlier startup investments via Melbourne's Genesis Pre-Seed fund.
Melbourne university funds backed a psychedelic medicines startup; six campus startups were showcased, and Tanarra Capital reported $100 million committed toward its alumni founders fund target.
Roundup of the week's Australian raises: Sitemate, Kashcade, Psychae Therapeutics, MediCann Health, Refilled and Upworth together banked $21.3 million across software, lending, psychedelic medicine, cannabis and drink dispensing.
Also Startup Daily·Startup Daily·SmartCompany·Forbes Australia